Phase 1 Trial Recruitment Complete for Atara’s ATA188 T-cell Immunotherapy for Progressive MS – Multiple Sclerosis News Today
|
Phase 1 Trial Recruitment Complete for Atara's ATA188 T-cell Immunotherapy for Progressive MS
Multiple Sclerosis News Today Atara Biotherapeutics recently published an update of the company's quarterly financial results and operational highlights, including the advancement of its T-cell based immunotherapy strategies for multiple sclerosis (MS) and cancer. One of the … |
